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Abstract 
The reported survival rates of patients with acute respiratory distress syndrome (ARDS) caused by human adenovirus 
(HAdV) pneumonia are poor. The results do not differ much in immunocompetent patients supported by extracor‑
poreal membrane oxygenation (ECMO). We report two immunocompetent patients with severe ARDS complicating 
HAdV pneumonia who were treated successfully and survived to discharge. Compared with previous cases, our cases 
might have benefited from several factors. First, the time interval between mechanical ventilator support and ECMO 
implantation was shorter. Second, we implemented conservative fluid management as recommended by the ARDS 
network using continuous renal replacement therapy (CRRT). Third, we administered an antiviral agent as early as pos‑
sible. A clinical trial of early ECMO with CRRT and the administration of cidofovir in patients with severe ARDS compli‑
cating HAdV pneumonia are needed to confirm our results.
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Background
Severe acute respiratory distress syndrome (ARDS) com-
plicating adenovirus pneumonia has been a concern in 
immunocompetent adults since CDC (2001) reported 
two adenovirus pneumonia-related deaths in 2001. Pre-
viously, human adenovirus (HAdV) serotypes 3 and 7 
accounted for the majority of severe infections; however, 
serotype 55 was recently identified as a pathogen of acute 
fatal pneumonia in immunocompetent adults (Yang et al. 
2009; Kajon et al. 2010; Gu et al. 2012; Zhang et al. 2012; 
Cao et  al. 2014). Although the mortality rate of HAdV 
pneumonia varies according to the study population and 
disease severity, a systemic review reported a mortality 
rate of 57.0%.
Extracorporeal membrane oxygenation (ECMO) has 
been used as rescue therapy for patients with severe 
ARDS caused by HAdV, but the outcome was not sat-
isfactory (Gu et al. 2012; Sun et al. 2014; Prodhan et al. 
2014). However, the greatest benefit of ECMO is protect-
ing the lungs from high-pressure mechanical ventilation 
and oxygen toxicity, minimizing on-going lung injury. 
Additionally, several studies have reported that among 
ECMO survivors, CRRT groups had a better fluid bal-
ance compared with non-CRRT groups (Cavagnaro et al. 
2007; Hoover et al. 2008; Blijdorp et al. 2009), and fluid 
overload at the end of ECMO was a predictor of a worse 
outcome (Gbadegesin et al. 2009). We believe that a low 
tidal volume and conservative fluid strategies are impor-
tant for ARDS patients, and could be achieved by the 
early initiation of ECMO support and CRRT. We present 
two cases of severe ARDS caused by HAdV pneumo-
nia for whom the early initiation of ECMO plus CRRT, 
together with an antiviral agent (cidofovir), was tried.
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Methods
The patient data were evaluated with the approval of 
the Institutional Review Board of the author’s hospital. 
Due to the purely observational, retrospective, and non-
interventional nature of this study, informed consent 
was deemed unnecessary and was not obtained. Patient 
records and information were anonymized and de-identi-
fied before analysis.
Between January and May 2015, three immunocompe-
tent adults (a 32-year-old man, 46-year-old woman, and 
60-year-old man) with HAdV pneumonia were admit-
ted to Hallym University Sacred Heart Hospital. Two of 
these patients were transferred to the ICU, because of 
severe refractory hypoxemia and our ECMO team was 
consulted. Severe ARDS was diagnosed using the Berlin 
criteria (Ferguson et  al. 2012): (1) new onset of respira-
tory symptoms within 1 week, or new or worsening symp-
toms during the previous week; (2) bilateral opacities on 
a chest radiograph or computed tomography (CT), not 
fully explained by pleural effusions, lobar/lung collapse, 
or nodules; (3) respiratory failure not fully explained by 
cardiac failure or fluid overload; and (4) an arterial oxygen 
tension to fraction of inspired oxygen (PaO2/FiO2) ratio 
≤100  mmHg on ventilator settings that include positive 
end-expiratory pressure (PEEP) ≥5 cm H2O. HAdV pneu-
monia was diagnosed when the following criteria were 
met: (1) symptoms of an acute (viral) lower respiratory 
tract illness; (2) newly developed lung infiltration on chest 
radiography or CT; and (3) detection of adenovirus DNA 
from sputum specimens or bronchoalveolar lavage (BAL) 
fluid using the polymerase chain reaction (PCR).
ECMO and CRRT management
Two patients required veno-venous (VV) ECMO support 
based on the following criteria: good premorbid function-
ing, PaO2/FiO2 <100 on FiO2 1.0 with a PEEP of >15 cm 
H2O or uncompensated hypercapnia with acidemia 
(pH < 7.25); and a high end-inspiratory plateau pressure 
(>35 cm Hg) despite application of the best standard care 
using a mechanical ventilator. The Centrifugal Rotaflow 
Pump® (Maquet, Hirrlingen, Germany) and 17–21Fr 
venous cannulas (DLP®; Medtronic or RMI®; Edward’s 
Lifesciences, Irvine, CA, USA) were used. Both common 
femoral veins were cannulated percutaneously using the 
Seldinger technique guided by fluoroscopy in the car-
diac catheterization laboratory. During ECMO, nafamo-
stat mesilate (SK Chemicals Life Science, Seoul, Korea 
licensed by Torii Pharmaceutical, Tokyo, Japan) was 
used for anticoagulation with a maintenance dose of 0.4–
1.5 mg/kg/h and a target activated partial thromboplastin 
time (aPTT) of 60–80 s. The CRRT machine was intro-
duced into the ECMO circuit by connecting the inlet 
line after the oxygenator and the outlet line before the 
oxygenator (Chen et al. 2014). The mechanical ventilator 
settings were as follows: inspiratory pressure, 10 cm H2O; 
PEEP, 10 cm H2O; respiration rate, 10/min; I/E ratio, 2:1; 
and FiO2, 0.21‒0.6. The target hematocrit was >30% and 
the platelet target >50,000‒100,000/mm3. Although a 
positive fluid balance was initially permitted up to 2–3 L/
day due to the patients’ unstable hemodynamic condi-
tions, a conservative fluid strategy, as recommended by 
the ARDS Clinical Trial Network, was followed thereaf-
ter (National Heart L et  al. 2006; Brodie and Bacchetta 
2011). Successful ECMO weaning was defined as patient 
survival for >24 h after ECMO removal.
Results
Patient 1
A 46-year-old healthy woman with a non-contributory 
medical history had a high fever, cough, and sputum 
for 5 days and was admitted to a local hospital with left 
lower lobe pneumonia. Despite administration of empiri-
cal antibiotic therapy comprising intravenous ceftriax-
one and clarithromycin, her symptoms persisted and she 
developed dyspnea; at this time the patient was referred 
to our hospital (Fig.  1). On admission, her vital signs 
were systolic blood pressure 120 mm Hg, heart rate 104 
beats/min, respiratory rate 24/min, and body tempera-
ture 39  °C. The white blood cell count was 11,900/mm3, 
C-reactive protein was 162.2  mg/L, and liver function 
tests were within normal ranges. By pulse oximetry, the 
initial oxygen saturation was 89% with O2 8  L via facial 
mask. On the second day of hospitalization, the consoli-
dation on chest X-ray was worse and her oxygen require-
ment markedly increased. She was transferred to the ICU 
and started on mechanical ventilation and a norepineph-
rine infusion (~0.6  μg/kg/min; Simplified Acute Physi-
ologic Score II [SAPS II], 35). On ICU day 2, HAdV was 
identified by PCR in a sputum specimen obtained at the 
time of admission, and she was given cidofovir 5 mL/kg/
week for 2  weeks. We also started intravenous methyl-
prednisolone at 1 mg/kg q 24 h, which was later tapered 
slowly. However, the severe hypoxia was not improved 
despite a FiO2 of 100% and a PEEP of 15  cm H2O (i.e., 
PaO2/FiO2  =  40  mmHg), and her plateau pressure was 
>35 mm H2O. We put her in a prone position, but this did 
not improve her severe hypoxemia. Therefore, we started 
VV ECMO in the patient with concomitant CRRT. The 
initial ECMO settings were as follows: blood flow 4.6 L/
min, sweep gas flow 6.0  L/min, and FiO2 1.0 (Table  1). 
Her hemodynamic findings stabilized after initiating VV 
ECMO. We performed BAL, and the cell differential in 
the BAL fluid was as follows: neutrophils 45%, lympho-
cytes 26%, macrophages 20%, and eosinophils 9%. Micro-
biological testing of the BAL specimen gave a positive 
PCR test for HAdV, while all tests for bacteria and other 
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viruses were negative. We continued the conservative 
fluid strategy throughout the ECMO treatment (Table 2) 
and her chest X-ray findings began to improve on ECMO 
day 4. She was extubated and allowed to awaken from 
the ECMO on day 5. On ICU day 16 (i.e., ECMO day 14), 
ECMO and CRRT were finally weaned and removed. 
Her net fluid balance was −2305  mL (−164.6  mL/day) 
during the ECMO period (Fig. 2). Subsequently, she was 
transferred to a general ward on ICU day 20 and finally 
discharged home. She was alive and had normal daily 
activities at the 1-year follow-up assessment.
Patient 2
A 60-year-old man with a history of hypertension, vari-
ant angina, and hyperthyroidism developed high fever, 
cough, sputum, myalgia and dyspnea 4  days before 
admission. He was admitted to our hospital with a pre-
sumptive diagnosis of community-acquired pneumonia 
and treated with empirical antibiotic therapy compris-
ing piperacillin–tazobactam and levofloxacin (Fig.  1). 
His systolic blood pressure was 100  mm Hg, heart rate 
126 beats/min, respiratory rate 36/min, and body tem-
perature 39  °C. The initial laboratory findings were as 
follows: WBC 14,500/mm3, platelets 237,000/mm3, CRP 
302.6  mg/L, BUN 29.8  mg/dL, and creatinine 1.18  mg/
dL. Liver function tests were within normal ranges. The 
initial O2 saturation was 85% and he received O2 (5  L/
min) via facial mask. On day 3, his chest X-ray findings 
were worse and his oxygen requirement was increased. 
The patient was transferred to the ICU and treated with 
a non-invasive positive pressure ventilator. However, his 
severe hypoxemia was not improved (SaO2 =  94% with 
FiO2 100% and respiratory rate  =  45/min), and he was 
intubated. On ICU day 2, his severe hypoxemia was not 
improved despite mechanical ventilation (i.e., PaO2/
FiO2 =  67.6 with a PEEP of 15  cm H2O), and his heart 
rate increased to 151 beats/min (SAPS II, 36). We decided 
to apply VV ECMO, and started CRRT for fluid manage-
ment. The initial ECMO settings were as follows: blood 
flow 5.0 L/min, sweep gas flow 4.5 L/min, and FiO2 1.0. 
On ECMO day 4, a PCR test for HAdV in a sputum sam-
ple taken at the time of admission was positive; based on 
this finding, the patient was administered cidofovir 5 mL/
kg/week. The cell differential in the BAL fluid was as fol-
lows: neutrophils 43%, lymphocytes 34%, macrophage 
22%, and eosinophils 1%. All tests of the BAL specimen 
for bacteria and viruses were negative. Although his 
blood gas oxygenation and chest X-ray showed an ini-
tial improvement during the early period of VV ECMO 
support, they were again worse on ECMO day 7 (Fig. 1). 
Fig. 1 Chest radiography of two patients with severe ARDS caused by adenovirus. a and e On admission day; b and f on ECMO day 1; c and g on 
ECMO day 7 and; d and h on day after ECMO weaning
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Therefore, we started treatment with methylpredni-
solone 2  mg/kg q 24  h, which was then tapered slowly. 
We attempted to maintain a conservative fluid strategy 
(Table 2) and the PaO2/FiO2 ratio and chest X-ray find-
ings began to improve from ECMO day 9. On ECMO 
day 12, a tracheostomy was performed and ECMO and 
CRRT were removed on ECMO day 24. His net fluid bal-
ance was +10,219  mL (+425.8  mL/day) throughout the 
ECMO treatment (Fig.  2). The patient was transferred 
to a general ward on ICU day 32 and finally discharged 
home. At his 1-year follow-up assessment, the patient 
was ambulatory and able to perform light housework.
Discussion
We successfully treated two patients diagnosed with ade-
novirus pneumonia with severe ARDS and suggest that 
such patients might benefit from early appropriate sup-
port using VV ECMO and CRRT.
Although no well-designed randomized controlled 
trials have proven its efficacy (Zapol et  al. 1979; Morris 
et  al. 1994, 2012), the conventional ventilatory support 
versus extracorporeal membrane oxygenation for severe 
adult respiratory failure (CESAR) trial and 2009 influenza 
A (H1N1) epidemic have promoted ECMO use worldwide 
(Peek et al. 2009; ANZ ECMO et al. 2009). To date, sev-
eral authors have reported ECMO use in severe ARDS 
caused by HAdV. Sun et al. (2014) described five patients 
with severe ARDS with confirmed HAdV-55 infection, 
four of whom received VV ECMO. Low et  al. (2013) 
reported three patients with confirmed HAdV-7 ARDS 
who were treated with VV ECMO; the reported survival 
rates were poor. Prodhan et al. (2014) also reported that 
only 62 (38.0%) of 163 children with adenovirus pneumo-
nia supported using ECMO survived. However, both of 
our patients survived throughout the period of ECMO 
support. Compared with previous studies, our cases 
might have benefited from several factors. First, the time 
interval between mechanical ventilator support and 
ECMO implantation was shorter. Second, we followed 
the conservative fluid management recommended by the 
Table 1 Clinical and hemodynamic parameters of two patients
ECMO extracorporeal membrane oxygenation, NC nasal cannula
Pre-ECMO ECMO day 1 ECMO day 3 ECMO day 7 ECMO day 10 ECMO day 14 Post ECMO 
weaning
Patient 1
 Arterial blood gas 
analysis
pH 7.40 7.49 7.464 7.46 7.43 7.44 7.40
PaCO2, mmHg 26.8 25.8 33.7 29.7 38.5 34.1 27.9
PaO2, mmHg 54.8 215.7 126.8 102.9 162.4 102.2 97.4





18 10 10 – – – –
PEEP, mmHg 15 10 10 – – – –
FiO2 1.0 0.3 0.3 0.3 by NC 0.3 by NC 0.3 by NC 0.3 by NC
 ECMO setting ECMO blood flow, 
L/min
– 4.6 4.5 4.4 3.0 2.0 –
ECMO FiO2, – 1.0 1.0 1.0 1.0 0.2 –
Sweep gas flow, 
L/min
– 6.0 4.0 4 4.0 0 –
Patient 2
 Arterial blood gas 
analysis
pH 7.38 7.42 7.43 7.47 7.45 7.46 7.41
PaO2, mmHg 33.5 30.8 32.9 35.1 40.0 32.7 38.6
PaCO2, mmHg 67.6 183.8 148.4 77.3 78.5 101.5 107.2





20 10 10 10 12 10 12
PEEP, mmHg 15 10 10 10 8 6 6
FiO2 0.9 0.6 0.35 0.45 0.45 0.45 0.35
 ECMO setting ECMO blood flow, 
L/min
– 5 5 4.58 2.5 3.4 –
ECMO FiO2, – 1.0 1.0 1.0 1.0 1.0 –
Sweep gas flow, 
L/min
– 4.5 4.5 9.5 6.5 5.8 –
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ARDS network, using CRRT support. Third, we adminis-
tered the antiviral agent as early as possible.
The most important role of ECMO support might be 
‘lung rest’ with a low tidal volume, thereby decreasing 
ventilator-induced lung injury (VILI). Therefore, the early 
initiation of ECMO seems to be an intriguing option to 
protect the lungs of these critically ill patients (MacLaren 
et al. 2012; Turner and Cheifetz 2013). In a case series in 
Low et  al. (2013), the duration of pre-ECMO mechani-
cal ventilation was 2, 5, and 16 days, while in Sun et al. 
(2014), it was 2–13 days, which were longer than in our 
two cases (i.e., 47 and 15 h, respectively). We also applied 
lung rest ventilation to the patients, as recommended by 
the Extracorporeal Life Support Organization (ELSO). 
Hence, we suggest that this early initiation of ECMO 
support might have played a role in our cases. However, 
ECMO has not been accepted as an established treat-
ment for adults with ARDS (Morris et al. 2010; Hirshberg 
et  al. 2013; Deutschman and Neligan 2016). Two rand-
omized clinical trials failed to show that ECMO was effi-
cacious in adults with ARDS (Zapol et  al. 1979; Morris 
et al. 1994). Hence, we cannot say that ECMO treatment 
was directly related to patient survival in our cases (Park 
et al. 2010); rather, conservative fluid management using 
CRRT could have played a critical role (National Heart 
L et al. 2006). Although patients undergoing ECMO and 
CRRT have an increased risk of mortality compared with 
those receiving ECMO only, Chen et  al. (2014) recently 
suggested that the combination of ECMO and CRRT is 
a safe, effective method for treating ECMO patients who 
have developed acute kidney disease. One advantage of 
CRRT is that it can improve fluid overload and electro-
lyte imbalance in critically ill patients. Moreover, recent 
studies demonstrated in porcine models that ECMO in 
combination with CRRT treatment could reduce inflam-
matory cytokines and ameliorate ECMO-induced acute 
kidney injury or better preserve lung parenchyma (Yimin 
et al. 2013; Shi et al. 2014). Our ECMO team also initi-
ated CRRT simultaneously with ECMO support due to 
its immunomodulatory effect and to improve the fluid/
electrolyte/acid–base balance. Although Wolf et  al. 
(2013) were concerned about precipitating intravascular 
depletion by CRRT at a time of maximal capillary leak-
age, we permitted, if needed, a positive fluid balance of up 
to 2–3 L in our cases on ECMO days 1–2. However, the 
total net fluid balance of the two cases during the entire 
ECMO period was −164.6 to 425.8 mL/day, respectively.
Regarding the treatment of severe HAdV pneumonia, 
no controlled trials have demonstrated the effectiveness 
of antiviral agents. Recently, Kim et  al. (2015) reported 
that six patients with severe HAdV pneumonia who had 
received cidofovir a median of 7.1  days after symptom 
onset recovered to discharge. They suggested that the 
early administration of cidofovir is an important treat-
ment option, especially in cases of HAdV-55 infection. In 
previous reports, however, many cases with HAdV infec-
tions did not receive cidofovir, and the few patients who 
received the agent had poor outcomes. In our cases, the 
time interval from symptom onset to cidofovir admin-
istration was 8–9  days, respectively. However, the clini-
cal, radiological, and laboratory findings of our patients 
improved gradually. The only adverse reaction was a skin 
rash in one patient. The effectiveness of cidofovir for 
severe HAdV pneumonia should be investigated further.
There were several limitations to this study. First, only 
two patients were reviewed due to the rarity of patients 
with HAdV pneumonia who receive ECMO support. 
Therefore, more experience is needed to draw a firm 
conclusion regarding the standard therapy. Second, the 
HAdV serotypes were not identified in our patients; 
therefore, the clinical efficacy of cidofovir for pneumo-
nia caused by HAdV of specific serotypes could not be 
Fig. 2 Daily net fluid balance of the two patients with severe ARDS caused by adenovirus
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determined. Despite these limitations, however, we sug-
gest that to reduce VILI and extravascular lung water, 
early initiation of concomitant VV ECMO and CRRT 
support should be considered in patients with severe 
ARDS complicating HAdV pneumonia.
Conclusions
We report two patients with severe ARDS complicating 
HAdV pneumonia who were treated successfully and 
survived to discharge. We suggest that this patient group 
might benefit from early appropriate support with VV 
ECMO plus CRRT and cidofovir administration. Further 
clinical analysis of this treatment strategy is needed to 
confirm our results.
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